Physician profile
Fred A Hurst
NPI 1700821949
$5,069.46
in general payments reported to CMS, 2019-2025
37 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $299 · 2021: $670 · 2022: $858 · 2023: $886 · 2024: $807 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,051.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $890.59 | 2021-2025 | |
| Glaxosmithkline, LLC. | $513.30 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $359.03 | 2021-2025 | |
| Pfizer INC. | $304.55 | 2019-2025 | |
| Astellas Pharma US INC | $291.88 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.41 | 2019-2024 | Xifaxan |
| Abbott Laboratories | $182.13 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $130.99 | 2020-2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.53 | 2019-2024 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $83.94 | 2021-2023 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $83.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $75.12 | 2019-2021 | |
| Amarin Pharma, INC. | $65.59 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.